GLUE
Monte Rosa Therapeutics, Inc. NASDAQ Listed Jun 24, 2021$18.31
-0.54%
vs $18.41
Mkt Cap $1.2B
52w Low $4.12
65.5% of range
52w High $25.77
50d MA $18.68
200d MA $15.84
P/E (TTM)
-39.8x
EV/EBITDA
—
P/B
6.5x
Debt/Equity
0.2x
ROE
8.5%
P/FCF
-55.3x
RSI (14)
40.50
ATR (14)
$1.20
Beta
1.64
50d MA
$18.68
200d MA
$15.84
Avg Volume
952.3K
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
CIK (SEC)
Phone
617 949 2643
645 Summer Street · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 20.39 | -0.7% | -2.8% | -2.1% | +4.5% | -5.7% | -0.8% | — |
| Mar 17, 2026 | AMC | -0.35 | -0.54 | -53.6% | 16.03 | -1.1% | -1.7% | +1.9% | -2.7% | -3.8% | -2.1% | — |
| Nov 6, 2025 | AMC | -0.37 | -0.33 | +9.9% | 13.01 | -2.2% | -5.4% | +14.2% | +1.8% | -1.1% | +1.1% | — |
| Aug 7, 2025 | AMC | -0.38 | -0.15 | +60.2% | 4.23 | -0.7% | +3.5% | -4.3% | +6.2% | -0.2% | -2.0% | — |
| May 8, 2025 | AMC | -0.00 | 0.57 | +9999.0% | 4.22 | +0.5% | -3.1% | +4.4% | -5.4% | -8.4% | +4.6% | — |
| Mar 20, 2025 | AMC | 0.02 | 0.23 | +1379.4% | 7.06 | -0.1% | -17.8% | +0.5% | -2.7% | -3.2% | -4.2% | — |
| Nov 7, 2024 | AMC | -0.49 | -0.29 | +40.8% | 9.53 | +3.0% | -2.8% | +8.1% | -8.8% | -5.5% | -1.7% | — |
| Aug 8, 2024 | AMC | -0.54 | -0.43 | +20.4% | 3.98 | +0.8% | -1.0% | +1.0% | +21.1% | -6.6% | +8.9% | — |
| May 9, 2024 | AMC | -0.57 | -0.53 | +7.0% | 5.18 | +0.8% | -6.4% | +2.1% | +1.0% | +4.6% | -0.2% | — |
| Mar 14, 2024 | AMC | -0.33 | -0.58 | -75.8% | 6.09 | +0.0% | +5.3% | +4.5% | +3.3% | +7.7% | +1.9% | — |
| Nov 9, 2023 | AMC | -0.72 | -0.70 | +2.8% | 3.30 | +0.0% | -2.7% | -4.8% | +11.6% | +7.9% | -12.0% | — |
| Aug 10, 2023 | AMC | -0.70 | -0.71 | -1.4% | 6.68 | +1.0% | +0.1% | -2.4% | +0.8% | -1.7% | -1.4% | — |
| May 11, 2023 | AMC | -0.68 | -0.65 | +4.4% | 5.85 | -2.2% | -2.9% | +3.0% | -4.4% | +1.1% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $16.03 | $15.86 | -1.1% | -1.7% | +1.9% | -2.7% | -3.8% | -2.1% |
| Mar 18 | Guggenheim | Maintains | Buy → Buy | — | $16.03 | $15.86 | -1.1% | -1.7% | +1.9% | -2.7% | -3.8% | -2.1% |
| Jan 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.99 | $23.99 | +0.0% | +0.3% | +0.1% | -1.5% | +3.1% | -0.9% |
| Jan 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $23.28 | $23.36 | +0.3% | +8.7% | -4.1% | -2.3% | +1.1% | +0.3% |
| Jan 8 | Guggenheim | Maintains | Buy → Buy | — | $23.28 | $23.36 | +0.3% | +8.7% | -4.1% | -2.3% | +1.1% | +0.3% |
| Dec 16 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $16.45 | $17.19 | +4.5% | +13.4% | -10.2% | -5.5% | -1.8% | +4.2% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.01 | $12.73 | -2.2% | -5.4% | +14.2% | +1.8% | -1.1% | +1.1% |
| Mar 21 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $7.06 | $7.05 | -0.1% | -17.8% | +0.5% | -2.7% | -3.2% | -4.2% |
| Mar 21 | Wedbush | Maintains | Outperform → Outperform | — | $7.06 | $7.05 | -0.1% | -17.8% | +0.5% | -2.7% | -3.2% | -4.2% |
| Dec 19 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $7.03 | $6.81 | -3.1% | -7.4% | +6.5% | +3.0% | -1.3% | +2.4% |
| Sep 12 | Wedbush | Maintains | Outperform → Outperform | — | $6.22 | $6.22 | +0.0% | -4.2% | +2.0% | -7.6% | +5.3% | +0.5% |
| Aug 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.94 | $3.98 | +1.0% | +1.0% | +21.1% | -6.6% | +8.9% | -4.5% |
| Jun 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.38 | $3.32 | -1.8% | +10.7% | +5.3% | -8.9% | +8.4% | -6.4% |
| May 22 | Wedbush | Maintains | Outperform → Outperform | — | $4.30 | $4.47 | +4.0% | -2.1% | -5.2% | +4.3% | +0.5% | -4.3% |
| Oct 19 | JP Morgan | Maintains | Overweight → Overweight | — | $3.43 | $3.36 | -2.0% | -8.9% | -12.3% | -3.3% | -2.6% | -3.1% |
| Aug 11 | Credit Suisse | Maintains | Neutral → Neutral | — | $6.68 | $6.75 | +1.0% | +0.1% | -2.4% | +0.8% | -1.7% | -1.4% |
| May 12 | Credit Suisse | Maintains | Neutral → Neutral | — | $5.85 | $5.72 | -2.2% | -2.9% | +3.0% | -4.4% | +1.1% | -1.9% |
| Mar 17 | Credit Suisse | Maintains | Neutral → Neutral | — | $7.01 | $6.87 | -2.0% | +3.0% | -3.9% | -2.3% | +3.2% | -0.6% |
| Jan 3 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $7.61 | $8.28 | +8.8% | +2.2% | -0.4% | -0.6% | +3.4% | -14.3% |
| Oct 13 | UBS | Maintains | Buy → Buy | — | $7.01 | $7.14 | +1.9% | +12.1% | -1.1% | +4.4% | +2.2% | -8.6% |
| Aug 22 | Credit Suisse | Maintains | Neutral → Neutral | — | $9.00 | $9.00 | +0.0% | -1.6% | +1.7% | +3.2% | -4.1% | -3.5% |
| Aug 15 | Jefferies | Maintains | Buy → Buy | — | $10.03 | $10.57 | +5.4% | -0.9% | -3.1% | -6.3% | +1.0% | -1.2% |
| May 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.91 | $7.76 | -1.9% | -2.3% | +6.0% | -6.8% | +12.6% | -4.9% |
| Apr 28 | Credit Suisse | Maintains | Neutral → Neutral | — | $11.66 | $11.74 | +0.7% | -4.5% | -2.2% | +9.6% | +0.4% | +2.0% |
| Feb 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $15.09 | $14.23 | -5.7% | -7.6% | -6.5% | -1.1% | +12.2% | +0.1% |
| Oct 14 | SVB Leerink | Maintains | Market Perform → Perform | — | $22.06 | $22.11 | +0.2% | +5.6% | -9.0% | +2.9% | +3.5% | +5.4% |
| Jul 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $19.29 | $19.80 | +2.6% | +2.7% | +8.5% | +1.0% | +2.1% | +5.5% |
| Jul 19 | JP Morgan | Maintains | Overweight → Overweight | — | $19.29 | $19.80 | +2.6% | +2.7% | +8.5% | +1.0% | +2.1% | +5.5% |
| Jul 19 | Guggenheim | Maintains | Buy → Buy | — | $19.29 | $19.80 | +2.6% | +2.7% | +8.5% | +1.0% | +2.1% | +5.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Townson Sharon | Chief Scientific Officer | Sell | 3,000 | $19.00 | $57K | 67,845 | — | — |
| Jun 17, 2026 | Champoux Jennifer | Chief Operating Officer | Sell | 2,176 | $19.00 | $41K | 62,371 | — | — |
| Jun 1, 2026 | Warmuth Markus | President & CEO | Sell | 468 | $19.73 | $9K | 594,538 | -0.85% | -2.29% |
| Jun 1, 2026 | Warmuth Markus | President & CEO | Sell | 4,998 | $19.41 | $97K | 595,006 | -0.85% | -2.29% |
| May 29, 2026 | Townson Sharon | Chief Scientific Officer | Sell | 6,000 | $19.87 | $119K | 67,845 | -9.81% | +3.85% |
| May 27, 2026 | Champoux Jennifer | Chief Operating Officer | Sell | 2,175 | $20.00 | $44K | 62,371 | +1.65% | -1.31% |
| May 22, 2026 | Champoux Jennifer | Chief Operating Officer | Sell | 2,176 | $19.00 | $41K | 62,371 | -0.16% | -9.81% |
| May 1, 2026 | Warmuth Markus | President & CEO | Sell | 5,467 | $18.92 | $103K | 600,004 | +5.37% | -5.68% |
8-K · 2.02
!! High
Monte Rosa Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Monte Rosa Therapeutics reported Q1 2026 results, providing investors with updated financial performance metrics and operational progress for evaluating the biopharmaceutical company's trajectory.
May 7
8-K
Unknown — 8-K Filing
Monte Rosa's three MGD programs entering Phase 2 trials represent validation of its platform technology and substantial clinical milestone achievement, potentially de-risking the pipeline and attracting investor confidence for biotech investors seeking exposure to early-stage therapeutic validation.
Mar 17
8-K
Monte Rosa Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful investor analysis based on this summary, as it only contains boilerplate language about an accountant's credentials with no material business information disclosed.
Feb 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 3,100,245 | $51M | New | Mar 2026 |
| 2 | Aisling Capital Management Lp | 1,555,664 | $26M | Added | Mar 2026 |
| 3 | Morgan Stanley | 1,611,060 | $25M | Added | Dec 2025 |
| 4 | Marshall Wace, Llp | 1,433,152 | $24M | Added | Mar 2026 |
| 5 | Bellevue Group Ag | 1,250,000 | $21M | New | Mar 2026 |
| 6 | Mpm Bioimpact Llc | 1,176,928 | $19M | — | Mar 2026 |
| 7 | Fmr Llc | 1,024,304 | $17M | Reduced | Mar 2026 |
| 8 | Silverarc Capital Management, Llc | 1,029,066 | $16M | Added | Dec 2025 |
| 9 | Braidwell Lp | 948,316 | $15M | New | Dec 2025 |
| 10 | Northern Trust Corp | 826,624 | $14M | Added | Mar 2026 |
| 11 | Alphabet Inc. | 744,948 | $12M | Reduced | Dec 2025 |
| 12 | Janus Henderson Group Plc | 685,926 | $11M | New | Mar 2026 |
| 13 | Aqr Capital Management Llc | 658,483 | $11M | Reduced | Mar 2026 |
| 14 | Arrowstreet Capital, Limited Partnership | 647,739 | $11M | Added | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 515,966 | $8M | New | Mar 2026 |
| 16 | Allspring Global Investments Holdings, Llc | 392,227 | $6M | Added | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 387,542 | $6M | Added | Mar 2026 |
| 18 | Renaissance Technologies Llc | 379,100 | $6M | New | Mar 2026 |
| 19 | Citadel Advisors Llc | 254,518 | $4M | Added | Mar 2026 |
| 20 | Adar1 Capital Management, Llc | 215,752 | $4M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.19B
Enterprise Value
$1.18B
P/E (TTM)
-39.80x
Forward P/E
—
PEG Ratio
0.64x
P/B
6.53x
P/S
12.30x
P/FCF
-55.31x
EV/EBITDA
—
Shares Out
83.1M
Financials (TTM)
Revenue
$123.7M
Net Income
-$38.6M
EBITDA
-$45.9M
Free Cash Flow
-$27.5M
Op Cash Flow
-$22.8M
EPS Basic
$-0.46
EPS Diluted
$-0.46
EPS Forward
$-1.59
Gross Margin
93.2%
Op Margin
-43.8%
Net Margin
-31.2%
Balance Sheet
Total Assets
$448.7M
Total Liab.
$215.6M
Total Equity
$233.1M
Cash
$377.1M
LT Debt
$34.8M
Book Value/Sh
$2.81
Debt/Equity
0.17x
Current Ratio
6.12
Quick Ratio
6.12
Returns & Growth
ROE
8.5%
ROA
4.6%
ROIC
-13.6%
Rev Growth YoY
+63.5%
EPS Growth YoY
+53.1%
Price Returns
2W
+5.5%
1M
+2.9%
3M
+11.0%
6M
+21.9%
12M
+371.5%
Technicals
52W High
$25.77
52W Low
$4.12
50d MA
$18.68
200d MA
$15.84
RSI (14)
40.50
ATR (14)
$1.20
Beta
1.64
Avg Volume
952K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$31.75
High
$37.00
Low
$22.00
Median
$34.00
Data updated apr 25, 2026 11:43am
· Source: financialmodelingprep.com